

WE CLAIM:

1. A method of treating psoriasis in a mammal comprising administering a VEGF antagonist to the mammal.

5

2. A method of treating psoriasis in a human comprising administering a VEGF antagonist to the human.

3. A method of treating psoriasis in a mammal comprising administering VEGFR1R2-FcΔC1(a) to the mammal.

4. A method of treating psoriasis in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

5. A method of reducing the severity of a psoriatic lesion in a mammal comprising administering a VEGF antagonist to the mammal.

6. A method of reducing the severity of a psoriatic lesion in a human comprising administering a VEGF antagonist to the human.

7. A method of reducing the severity of a psoriatic lesion in a mammal comprising administering VEGFR1R2-FcΔC1(a) to the mammal.

8. A method of reducing the severity of a psoriatic lesion in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

10
15
20
25

15. A method of reversing epidermal hyperplasia associated with psoriasis in a human comprising administering a VEGF antagonist to the human.

5 16. A method of reversing epidermal hyperplasia associated with psoriasis in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

17. A method of treating parakeratosis associated with psoriasis in a human comprising administering a VEGF antagonist to the human.

18. A method of treating parakeratosis associated with psoriasis in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

15 19. A method of treating microabcess associated with psoriasis in a human comprising administering a VEGF antagonist to the human.

20. A method of treating microabcess associated with psoriasis in a human comprising administering VEGFR1R2-FcΔC1(a) to the human.

20 21. A method of decreasing reteridges associated with psoriasis in a human comprising administering a VEGF antagonist to the human.

22. A method of decreasing reteridges associated with psoriasis in a
25 human comprising administering VEGFR1R2-FcΔC1(a) to the human.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500

- 23. A method of treating inflammatory skin disease in a human comprising administering to the human VEGFR1R2-FcΔC1(a).
- 24. A method of preventing the infiltration of lymphocytes from the dermis into the epidermis of a human comprising administering VEGFR1R2-FcΔC1(a) to the human.
- 25. The method of any one of claims 1-24 wherein the administration is topical administration.
- 26. The method of any one of claims 1-24 wherein the administration is subcutaneous administration.
- 27. The method of any one of claims 1-24 wherein the administration is intramuscular, intranasal, intrathecal, intraarterial, intravenous, transvaginal, transdermal, or transanal administration.
- 28. The use of a VEGF antagonist to treat psoriasis in a mammal.
- 29. The use of a VEGF antagonist to treat psoriasis in a human.
- 30. The use of VEGFR1R2-FcΔC1(a) to treat psoriasis in a human.
- 31. A method of enhancing wound healing in a human comprising administering a VEGF antagonist to the human.

32. A method of enhancing wound healing in a human comprising administering VEGFR1R2-Fc Δ C1(a) to the human.

33. The method of any one of claims 31 or 32 wherein the
5 administration is topical administration.

34. The method of any one of claims 31 or 32 wherein the administration is subcutaneous administration.

35. The method of any one of claims 31 or 32 wherein the
10 administration is intramuscular, intranasal, intrathecal, intraarterial, intravenous, transvaginal, transdermal, or transanal administration.

36. The use of a VEGF antagonist to enhance wound healing in a human.

37. The use of VEGFR1R2-Fc Δ C1(a) to enhance wound healing in a
15 human.